{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:42:32Z","timestamp":1791247352020,"version":"4.1.0"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T00:00:00Z","timestamp":1655251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research United Kingdom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Biosci."],"abstract":"<jats:p>\n                    Treatment with HSV1716\n                    <jats:italic>via<\/jats:italic>\n                    intralesional administration has proven successful for melanoma patients with the hope that oncolytic virotherapy would become another weapon in the systemic anticancer therapy (SACT) arsenal. In addition to challenges surrounding the systemic delivery of oncolytic viruses (OVs), problems associated with its\n                    <jats:italic>in vivo<\/jats:italic>\n                    modeling have resulted in low predictive power, contributing to the observed disappointing clinical efficacy. As OV\u2019s efficacy is elicited through interaction with the immune system, syngeneic orthotopic mouse models offer the opportunity to study these with high reproducibility and at a lower cost; however, inbred animals display specific immune characteristics which may confound results. The systemic delivery of HSV1716 was, therefore, assessed in multiple murine models of breast cancer. Tolerability to the virus was strain-dependent with C57\/Bl6, the most tolerant and Balb\/c experiencing lethal side effects, when delivered intravenously. Maximum tolerated doses were not enough to demonstrate efficacy against tumor growth rates or survival of Balb\/c and FVB mouse models; therefore; the most susceptible strain (Balb\/c mice) was treated with immunomodulators prior to virus administration in an attempt to reduce side effects. These studies demonstrate the number of variables to consider when modeling the efficacy of OVs and the complexities involved in their interpretation for translational purposes. By reporting these observations, we have potentially revealed a role for T-cell helper polarization in viral tolerability. Importantly, these findings were translated to human studies, whereby a Th1 cytokine profile was expressed in pleural effusions of patients that responded to HSV1716 treatment for malignant pleural mesothelioma with minimal side effects, warranting further investigation as a biomarker for predictive response.\n                  <\/jats:p>","DOI":"10.3389\/fmolb.2022.889395","type":"journal-article","created":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T04:08:48Z","timestamp":1655266128000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Inconsistencies in Modeling the Efficacy of the Oncolytic Virus HSV1716 Reveal Potential Predictive Biomarkers for Tolerability"],"prefix":"10.3389","volume":"9","author":[{"given":"Faith","family":"Howard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Conner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Danson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munitta","family":"Muthana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/jco.2014.58.3377","article-title":"Talimogene Laherparepvec Improves Durable Response Rate in Patients with Advanced Melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"Jco"},{"key":"B2","doi-asserted-by":"publisher","first-page":"4169","DOI":"10.1245\/s10434-016-5286-0","article-title":"Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial","volume":"23","author":"Andtbacka","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1007\/s00262-021-02897-5","article-title":"Modeling Human Tumor-Immune Environments In Vivo for the Preclinical Assessment of Immunotherapies","volume":"70","author":"Bareham","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"B4","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2174\/1874226200902010079","article-title":"Immunodeficient Mouse Models: An Overview","volume":"2","author":"Beliz\u00e1rio","year":"2009","journal-title":"Toij"},{"key":"B5","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3389\/fimmu.2019.00168","article-title":"Cold Tumors: A Therapeutic Challenge for Immunotherapy","volume":"10","author":"Bonaventura","year":"2019","journal-title":"Front. Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"4974","DOI":"10.4049\/jimmunol.167.9.4974","article-title":"1\u03b1,25-Dihydroxyvitamin D3 Has a Direct Effect on Naive CD4+ T Cells to Enhance the Development of Th2 Cells","volume":"167","author":"Boonstra","year":"2001","journal-title":"J. Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1126\/scitranslmed.aao1641","article-title":"Neoadjuvant Oncolytic Virotherapy before Surgery Sensitizes Triple-Negative Breast Cancer to Immune Checkpoint Therapy","volume":"10","author":"Bourgeois-Daigneault","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/nejm199212033272305","article-title":"Vitamin D3and Calcium to Prevent Hip Fractures in Elderly Women","volume":"327","author":"Chapuy","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1089\/10430340050083289","article-title":"Pre-existent Adenovirus Antibody Inhibits Systemic Toxicity and Antitumor Activity of CN706 in the Nude Mouse LNCaP Xenograft Model: Implications and Proposals for Human Therapy","volume":"11","author":"Chen","year":"2000","journal-title":"Hum. Gene Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1038\/gt.2008.121","article-title":"A Strategy for Systemic Delivery of the Oncolytic Herpes Virus HSV1716: Redirected Tropism by Antibody-Binding Sites Incorporated on the Virion Surface as a Glycoprotein D Fusion Protein","volume":"15","author":"Conner","year":"2008","journal-title":"Gene Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.lungcan.2020.10.007","article-title":"Oncolytic Herpesvirus Therapy for Mesothelioma - A Phase I\/IIa Trial of Intrapleural Administration of HSV1716","volume":"150","author":"Danson","year":"2020","journal-title":"Lung Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1038\/nm.2454","article-title":"Tumor Grafts Derived from Women with Breast Cancer Authentically Reflect Tumor Pathology, Growth, Metastasis and Disease Outcomes","volume":"17","author":"Derose","year":"2011","journal-title":"Nat. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1196\/annals.1321.010","article-title":"Glucocorticoids and the Th1\/Th2 Balance","volume":"1024","author":"Elenkov","year":"2004","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","article-title":"The Immune Contexture in Human Tumours: Impact on Clinical Outcome","volume":"12","author":"Fridman","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"101029","DOI":"10.1016\/j.tranon.2021.101029","article-title":"Improved Survival in Several Cancers with Use of H1-Antihistamines Desloratadine and Loratadine","volume":"14","author":"Fritz","year":"2021","journal-title":"Transl. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to Treat Immune Hot, Altered and Cold Tumours with Combination Immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"B17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40425-018-0371-5","article-title":"Dexamethasone-induced Immunosuppression: Mechanisms and Implications for Immunotherapy","volume":"6","author":"Giles","year":"2018","journal-title":"J. Immunother. cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1002\/cncr.32966","article-title":"Vitamin D Intake Is Associated with Decreased Risk of Immune Checkpoint Inhibitor\u2010induced Colitis","volume":"126","author":"Grover","year":"2020","journal-title":"Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1007\/s12032-010-9606-0","article-title":"Continuous Systemic Corticosteroids Do Not Affect the Ongoing Regression of Metastatic Melanoma for More Than Two Years Following Ipilimumab Therapy","volume":"28","author":"Harmankaya","year":"2011","journal-title":"Med. Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"596166","DOI":"10.3389\/fcimb.2020.596166","article-title":"Viral Infections, the Microbiome, and Probiotics","volume":"10","author":"Harper","year":"2020","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41374-018-0137-1","article-title":"Characterization of Immune Cell Subtypes in Three Commonly Used Mouse Strains Reveals Gender and Strain-specific Variations","volume":"99","author":"Hensel","year":"2019","journal-title":"Lab. Invest."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1200\/jco.2013.31.15_suppl.3000","article-title":"A Study of MPDL3280A, an Engineered PD-L1 Antibody in Patients with Locally Advanced or Metastatic Tumors","volume":"31","author":"Herbst","year":"2013","journal-title":"Jco"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e2104763","DOI":"10.1002\/smll.202104763","article-title":"Nanobugs as Drugs: Bacterial Derived Nanomagnets Enhance Tumor Targeting and Oncolytic Activity of HSV-1 Virus","volume":"18","author":"Howard","year":"2022","journal-title":"Small"},{"key":"B24","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2217\/nnm-2019-0323","article-title":"Designer Nanocarriers for Navigating the Systemic Delivery of Oncolytic Viruses","volume":"15","author":"Howard","year":"2020","journal-title":"Nanomedicine"},{"key":"B25","doi-asserted-by":"publisher","first-page":"102506","DOI":"10.1016\/j.nano.2021.102506","article-title":"Targeting Circulating Monocytes with CCL2-Loaded Liposomes Armed with an Oncolytic Adenovirus","volume":"40","author":"Iscaro","year":"2022","journal-title":"Nanomedicine"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.2174\/1381612825666190708214240","article-title":"Nanoparticles: Properties and Applications in Cancer Immunotherapy","volume":"25","author":"Iscaro","year":"2019","journal-title":"Cpd"},{"key":"B27","doi-asserted-by":"publisher","first-page":"611","DOI":"10.2217\/imt.15.35","article-title":"Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Melanoma","volume":"7","author":"Johnson","year":"2015","journal-title":"Immunotherapy"},{"key":"B28","doi-asserted-by":"crossref","first-page":"7470","DOI":"10.4049\/jimmunol.162.12.7470","article-title":"Effect of an Orally Active Th1\/Th2 Balance Modulator, M50367, on IgE Production, Eosinophilia, and Airway Hyperresponsiveness in Mice","volume":"162","author":"Kato","year":"1999","journal-title":"J. Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"834841","DOI":"10.3389\/fmolb.2022.834841","article-title":"Talimogene Laherparepvec: Moving from First-In-Class to Best-In-Class","volume":"9","author":"Kaufman","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"S134","DOI":"10.4161\/cbt.213","article-title":"Human Tumor Xenografts as Predictive Preclinical Models for Anticancer Drug Activity in Humans: Better Than Commonly Perceived-But They Can Be Improved","volume":"2","author":"Kerbel","year":"2003","journal-title":"Cancer Biol. Ther."},{"key":"B31","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1023\/a:1006140513233","article-title":"Orthotopic Models Are Necessary to Predict Therapy of Transplantable Tumors in Mice","volume":"17","author":"Killion","year":"1998","journal-title":"Cancer Metastasis Rev."},{"key":"B32","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ccell.2021.11.002","article-title":"The Allergy Mediator Histamine Confers Resistance to Immunotherapy in Cancer Patients via Activation of the Macrophage Histamine Receptor H1","volume":"40","author":"Li","year":"2022","journal-title":"Cancer Cell."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1002\/hed.20840","article-title":"Potential for Efficacy of the Oncolytic Herpes Simplex Virus 1716 in Patients with Oral Squamous Cell Carcinoma","volume":"30","author":"Mace","year":"2008","journal-title":"Head. Neck"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1136\/jitc-2020-001486","article-title":"Clinical Landscape of Oncolytic Virus Research in 2020","volume":"8","author":"Macedo","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s40425-018-0479-7","article-title":"High and Low Mutational Burden Tumors versus Immunologically Hot and Cold Tumors and Response to Immune Checkpoint Inhibitors","volume":"6","author":"Maleki Vareki","year":"2018","journal-title":"J. Immunother. cancer"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e1500108","DOI":"10.1080\/2162402x.2018.1500108","article-title":"Contrasting Impact of Corticosteroids on Anti-PD-1 Immunotherapy Efficacy for Tumor Histologies Located within or outside the Central Nervous System","volume":"7","author":"Maxwell","year":"2018","journal-title":"Oncoimmunology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.4049\/jimmunol.172.5.2731","article-title":"Of Mice and Not Men: Differences between Mouse and Human Immunology","volume":"172","author":"Mestas","year":"2004","journal-title":"J. Immunol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.3390\/cancers12071915","article-title":"Humanized Mice Are Precious Tools for Preclinical Evaluation of CAR T and CAR NK Cell Therapies","volume":"12","author":"Mhaidly","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1158\/0008-5472.can-10-2349","article-title":"Use of Macrophages to Target Therapeutic Adenovirus to Human Prostate Tumors","volume":"71","author":"Muthana","year":"2011","journal-title":"Cancer Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"8009","DOI":"10.1038\/ncomms9009","article-title":"Directing Cell Therapy to Anatomic Target Sites In Vivo with Magnetic Resonance Targeting","volume":"6","author":"Muthana","year":"2015","journal-title":"Nat. Commun."},{"key":"B41","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1007\/s12265-013-9496-6","article-title":"T Helper Cell Polarization in Healthy People: Implications for Cardiovascular Disease","volume":"6","author":"Olson","year":"2013","journal-title":"J. Cardiovasc. Trans. Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1073\/pnas.040557897","article-title":"Engineered Herpes Simplex Virus Expressing IL-12 in the Treatment of Experimental Murine Brain Tumors","volume":"97","author":"Parker","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1742-4933-5-1","article-title":"Differential Effects of Age on Circulating and Splenic Leukocyte Populations in C57BL\/6 and BALB\/c Male Mice","volume":"5","author":"Pinchuk","year":"2008","journal-title":"Immun. Ageing"},{"key":"B44","doi-asserted-by":"publisher","first-page":"5011","DOI":"10.1200\/jco.2014.32.15_suppl.5011","article-title":"Inhibition of PD-L1 by MPDL3280A and Clinical Activity in Pts with Metastatic Urothelial Bladder Cancer (UBC)","volume":"32","author":"Powles","year":"2014","journal-title":"Jco"},{"key":"B45","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1093\/ilar\/ily026","article-title":"Immune Relevant and Immune Deficient Mice: Options and Opportunities in Translational Research","volume":"59","author":"Radaelli","year":"2018","journal-title":"ILAR J."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.ymthe.2018.01.019","article-title":"Pre-existing Immunity to Oncolytic Virus Potentiates its Immunotherapeutic Efficacy","volume":"26","author":"Ricca","year":"2018","journal-title":"Mol. Ther."},{"key":"B47","doi-asserted-by":"publisher","first-page":"7577","DOI":"10.1126\/scitranslmed.aam7577","article-title":"Intravenous Delivery of Oncolytic Reovirus to Brain Tumor Patients Immunologically Primes for Subsequent Checkpoint Blockade","volume":"10","author":"Samson","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/s41416-019-0574-7","article-title":"The Lytic Activity of VSV-GP Treatment Dominates the Therapeutic Effects in a Syngeneic Model of Lung Cancer","volume":"121","author":"Schreiber","year":"2019","journal-title":"Br. J. Cancer"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.2353\/ajpath.2008.070776","article-title":"Genetically Programmed Biases in Th1 and Th2 Immune Responses Modulate Atherogenesis","volume":"172","author":"Schulte","year":"2008","journal-title":"Am. J. Pathology"},{"key":"B50","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1093\/ilar\/ilw002","article-title":"Preclinical Mouse Models for Analysis of the Therapeutic Potential of Engineered Oncolytic Herpes Viruses","volume":"57","author":"Speranza","year":"2016","journal-title":"ILAR J."},{"key":"B51","doi-asserted-by":"publisher","first-page":"3566","DOI":"10.1158\/1078-0432.ccr-16-2900","article-title":"Intratumoral Injection of HSV1716, an Oncolytic Herpes Virus, Is Safe and Shows Evidence of Immune Response and Viral Replication in Young Cancer Patients","volume":"23","author":"Streby","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"B52","doi-asserted-by":"publisher","first-page":"594963","DOI":"10.3389\/fimmu.2020.594963","article-title":"Virus Infections and Host Metabolism-Can We Manage the Interactions?","volume":"11","author":"Sumbria","year":"2020","journal-title":"Front. Immunol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/mt.2013.238","article-title":"Immunogenic HSV-Mediated Oncolysis Shapes the Antitumor Immune Response and Contributes to Therapeutic Efficacy","volume":"22","author":"Workenhe","year":"2014","journal-title":"Mol. Ther."},{"key":"B54","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1038\/mt.2016.167","article-title":"Robust Oncolytic Virotherapy Induces Tumor Lysis Syndrome and Associated Toxicities in the MPC-11 Plasmacytoma Model","volume":"24","author":"Zhang","year":"2016","journal-title":"Mol. Ther."}],"container-title":["Frontiers in Molecular Biosciences"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2022.889395\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T03:29:08Z","timestamp":1675826948000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2022.889395\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,15]]},"references-count":54,"alternative-id":["10.3389\/fmolb.2022.889395"],"URL":"https:\/\/doi.org\/10.3389\/fmolb.2022.889395","relation":{},"ISSN":["2296-889X"],"issn-type":[{"value":"2296-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,15]]},"article-number":"889395"}}